ECSP034598A - Compuesto lactamico - Google Patents

Compuesto lactamico

Info

Publication number
ECSP034598A
ECSP034598A EC2003004598A ECSP034598A ECSP034598A EC SP034598 A ECSP034598 A EC SP034598A EC 2003004598 A EC2003004598 A EC 2003004598A EC SP034598 A ECSP034598 A EC SP034598A EC SP034598 A ECSP034598 A EC SP034598A
Authority
EC
Ecuador
Prior art keywords
lactamic
compound
procedures
methyl
preparing
Prior art date
Application number
EC2003004598A
Other languages
English (en)
Spanish (es)
Inventor
Gary Lowell Engel
James E Audia
Stacey Leihg Mcdaniel
Thomas Mitchell Koenig
David Mitchell
James Abraham Aikins
Lynne Ann Buccilli
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP034598A publication Critical patent/ECSP034598A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
EC2003004598A 2000-11-17 2003-05-13 Compuesto lactamico ECSP034598A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17

Publications (1)

Publication Number Publication Date
ECSP034598A true ECSP034598A (es) 2003-06-25

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004598A ECSP034598A (es) 2000-11-17 2003-05-13 Compuesto lactamico

Country Status (33)

Country Link
US (1) US20040248878A1 (https=)
EP (1) EP1353910B1 (https=)
JP (1) JP4116431B2 (https=)
KR (1) KR20030045194A (https=)
CN (2) CN100516047C (https=)
AR (1) AR031356A1 (https=)
AT (1) ATE362919T1 (https=)
AU (2) AU2002224321B2 (https=)
BR (1) BR0115424A (https=)
CA (1) CA2425497C (https=)
CY (1) CY1106682T1 (https=)
CZ (1) CZ20031340A3 (https=)
DE (1) DE60128587T2 (https=)
DK (1) DK1353910T3 (https=)
DZ (1) DZ3454A1 (https=)
EA (1) EA006919B1 (https=)
EC (1) ECSP034598A (https=)
ES (1) ES2286162T3 (https=)
HR (1) HRP20030385A2 (https=)
HU (1) HUP0301862A3 (https=)
IL (1) IL155275A0 (https=)
MX (1) MXPA03004250A (https=)
MY (1) MY141607A (https=)
NO (1) NO325217B1 (https=)
PE (1) PE20020798A1 (https=)
PL (1) PL211018B1 (https=)
PT (1) PT1353910E (https=)
SK (1) SK287794B6 (https=)
SV (1) SV2003000741A (https=)
TW (1) TWI235151B (https=)
UA (1) UA77165C2 (https=)
WO (1) WO2002040451A2 (https=)
ZA (1) ZA200303411B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
EP2133340B1 (en) 2002-12-20 2013-01-16 Glaxo Group Limited Novel benzazepine derivatives
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US8114886B2 (en) 2005-04-08 2012-02-14 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
US8258302B2 (en) * 2006-01-31 2012-09-04 Api Corporation Method for producing benzazepinone
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
BR112022018987A2 (pt) 2020-03-26 2022-11-01 Seagen Inc Métodos de tratamento de mieloma múltiplo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002100B1 (ru) * 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
JP2003513958A (ja) * 1999-11-09 2003-04-15 イーライ・リリー・アンド・カンパニー β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物

Also Published As

Publication number Publication date
CA2425497A1 (en) 2002-05-23
ZA200303411B (en) 2004-08-02
CN100516047C (zh) 2009-07-22
IL155275A0 (en) 2003-11-23
SK287794B6 (sk) 2011-10-04
CZ20031340A3 (cs) 2004-06-16
JP2004521084A (ja) 2004-07-15
KR20030045194A (ko) 2003-06-09
UA77165C2 (en) 2006-11-15
CA2425497C (en) 2010-08-17
AU2432102A (en) 2002-05-27
PT1353910E (pt) 2007-08-20
JP4116431B2 (ja) 2008-07-09
WO2002040451A3 (en) 2003-08-28
EP1353910B1 (en) 2007-05-23
EA200300579A1 (ru) 2003-12-25
DE60128587D1 (de) 2007-07-05
BR0115424A (pt) 2003-10-21
AR031356A1 (es) 2003-09-17
CN1575282A (zh) 2005-02-02
MXPA03004250A (es) 2003-09-22
MY141607A (en) 2010-05-31
NO20032215L (no) 2003-07-16
US20040248878A1 (en) 2004-12-09
ATE362919T1 (de) 2007-06-15
TWI235151B (en) 2005-07-01
PE20020798A1 (es) 2002-09-06
AU2002224321B2 (en) 2006-10-19
DZ3454A1 (fr) 2002-05-23
CY1106682T1 (el) 2012-05-23
PL360991A1 (en) 2004-09-20
SV2003000741A (es) 2003-01-13
HUP0301862A2 (hu) 2003-09-29
CN101624372A (zh) 2010-01-13
SK5432003A3 (en) 2004-09-08
PL211018B1 (pl) 2012-03-30
DE60128587T2 (de) 2008-01-31
EA006919B1 (ru) 2006-04-28
WO2002040451A2 (en) 2002-05-23
HUP0301862A3 (en) 2007-09-28
EP1353910A2 (en) 2003-10-22
DK1353910T3 (da) 2007-09-10
NO20032215D0 (no) 2003-05-15
ES2286162T3 (es) 2007-12-01
HRP20030385A2 (en) 2003-08-31
NO325217B1 (no) 2008-02-25

Similar Documents

Publication Publication Date Title
ECSP034598A (es) Compuesto lactamico
HUS2000011I1 (hu) A 2,4-pirimidin-diamin vegyületek elõgyógyszerei és alkalmazásuk
ECSP034600A (es) Compuestos de lactama
ATE433447T1 (de) Pyrimiidinverbindungen
CY1117639T1 (el) Φαρμακευτικες συνθεσεις βασιζομενες επι κρυσταλλικης μορφης i της 5-αζακυτιδινης
PL2207786T3 (pl) 2'-fluoro-2'-deoksy tetrahydrouryny jako inhibitory dezaminazy cytydyny
GT200300040A (es) Composicion de ziprasidona y controles sinteticos
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
ECSP066467A (es) Formas Polimórficas de 3-(4-amino-1-Oxo-1-3 DIhidroisoindol-2-IL)-Piperidin-2,6-Diona
MA29135B1 (fr) Potentialisateurs de recepteurs du glutamate
DOP2002000422A (es) Agentes antibacterianos.
AR030893A1 (es) Uso combinado de inhibidores de acetilcolinesterasa y agonistas inversos de gabaa para el tratamiento de trastornos cognitivos
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
DE60122944D1 (de) Mikronisierter zolpidem Hemitartrat
UY30030A1 (es) Derivados sustituidos de la 8-piracin-2-il-1,2,4,4a-tetrahidro-2´h, 6h-espiro (1,4-oxacin(4,3-a)quinolin-5,5´-pirimidin)-2´, 4´, 6´ (1´h, 3´h)-tiona, composiciones y aplicaciones
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
HRP20080529T3 (en) Amide prodrug of gemcitabine, compositions and use thereof
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
MXPA05008960A (es) Oxazolidinonas de indolona antibacteriales, intermedios para su preparacion y composiciones farmaceuticas que las contienen.
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
BR112022016359A2 (pt) Formas cristalinas de um composto farmacêutico
AU3324201A (en) Tosylproline analogs as thymidylate synthase inhibitors
DOP2002000386A (es) Agentes antibacterianos